Fort Sheridan Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Fort Sheridan Advisors's VRTX Position: Q1 2026 in Review
Fort Sheridan Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, selling an estimated $153K and leaving 1,674 shares worth $748K. The position accounts for 0.09% of the portfolio, ranked #141.
Fort Sheridan Advisors first reported a position in VRTX in Q2 2020 and has held it in 21 quarters since. The position peaked at $1.18M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Fort Sheridan Advisors held 1,674 shares of Vertex Pharmaceuticals worth $748K as of Q1 2026.
- Fort Sheridan Advisors sold 328 Vertex Pharmaceuticals shares in Q1 2026, an estimated $153K.
- Vertex Pharmaceuticals made up 0.09% of Fort Sheridan Advisors's portfolio in Q1 2026, its #141 holding.
- Fort Sheridan Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
- Fort Sheridan Advisors's Vertex Pharmaceuticals position peaked at $1.18M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Fort Sheridan Advisors's 13F filing for Q1 2026, filed 6 May 2026.